Evidence map›Paper›PMID 40244244›Full record

ArticleInternational journal of molecular sciences2025

The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer's Disease.

Wei Wuli, Hsueh-Hui Yang, Tzyy-Wen Chiou, Peng Yeong Woon, Yue-Xuan Xu, Cynthia Tjandra, Ivan Wijaya, Horng-Jyh Harn, Shinn-Zong Lin

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Wei WuliBioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.ORCID 0000-0003-3033-6552
Hsueh-Hui YangDepartment of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.
Tzyy-Wen ChiouDepartment of Life Science, National Dong Hwa University, Hualien 974301, Taiwan.
Peng Yeong WoonDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan.ORCID 0009-0002-3469-6651
Yue-Xuan XuBioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.
Cynthia TjandraDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan.ORCID 0009-0005-4018-9244
Ivan WijayaDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan.
Horng-Jyh HarnDepartment of Pathology, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.
Shinn-Zong LinDepartment of Neurology, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.ORCID 0000-0002-4601-9933

Funding

Gwo Xi Stem Cell Applied Technology Co., Ltd IAC-RD-21-002National Science and Technology Council NSTC 113-2314-B-303-005
6 · The paper itself

Abstract

Adipose-derived mesenchymal stem cells (ADSCs) have exhibited promising therapeutic potential in Alzheimer's disease (AD), although the underlying mechanisms remain poorly understood. Previously established Alzheimer's disease neuron models derived from Ts21-induced pluripotent stem cells (Ts21-iPSCs) have been shown to exhibit progressive amyloid beta accumulation during neuronal differentiation. In this study, we employed a Transwell co-culture system to investigate the interaction between neurons derived from Ts21-iPSCs and ADSCs. Our findings revealed that co-culture with ADSCs significantly enhanced the survival rate of AD neurons. Proteomics analysis identified significant upregulation of left-right determination factor 2 (LEFTY2) protein in the co-culture medium. Supplementation with 2 nM LEFTY2 markedly improved the survival and growth of AD neurons. Furthermore, LEFTY2 effectively downregulates the expression of apolipoprotein E4 and amyloid beta 1-42, along with attenuating phosphorylated tau231 levels in AD neurons. These results suggest the potential of LEFTY2 as a promising therapeutic candidate for Alzheimer's disease.

Indexed as

Adipose TissueAlzheimer DiseaseLeft-Right Determination FactorsMesenchymal Stem CellsAmyloid beta-PeptidesApolipoprotein E4Cell DifferentiationCells, CulturedCell SurvivalCoculture TechniquesHumansInduced Pluripotent Stem CellsNeuronsPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4Left-Right Determination FactorsPeptide Fragmentstau Proteinsadipose derived mesenchymal stem cellsAlzheimer’s diseaseapolipoprotein E4left–right determination factor 2Ts21 induced pluripotent stem cells

Identifiers

PMID40244244
PMCPMC11990000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.